## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-ppis`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-ppis/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-ppis/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-ppis/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-ppis/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-ppis/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-ppis/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-ppis` v2 · content_hash `ac9e42bb0adb351c…` · thread_head genesis · 24 DIVs
- **thesis (c1):** Long-term PPI use is associated with vitamin B12, magnesium, and calcium deficiencies in observational data.
  - c3 [human/active] Human trials of SS-31 exist for primary mitochondrial myopathy and heart failure with mixed primary endpoint results; recent approval for Barth syndrome.
  - c2 [preclinical/active] SS-31 binds cardiolipin in the inner mitochondrial membrane and reduces ROS in preclinical models.
  - c4 [mechanistic/active] No human trials examine SS-31 in PPI users.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-ppis/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-ppis/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-ppis`
- **title:** SS-31 (Elamipretide) for PPI Users: Mitochondrial Pathways and Drug Context
- **url:** https://miscsubjects.com/a/ss-31-ppis
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:07.582Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have PPIs (omeprazole, etc.)

Long-term PPI use centers on acid suppression in the stomach. This reduces acid production but can lead to downstream effects on nutrient absorption and mucosal health. Observational data link extended use to deficiencies in vitamin B12, magnesium, and calcium. These shortfalls can impair cellular energy processes and tissue maintenance over time.

Mitochondria rely on adequate cofactors for ATP generation and antioxidant defense. When absorption dips, mitochondrial efficiency may decline in some contexts. One line of discussion notes that proton pumps exist in mitochondria too, raising the possibility of broader effects beyond the stomach, though this remains indirect. The net result is a potential imbalance where repair processes face extra hurdles while symptoms of reflux stay managed.

## Why SS-31 (Elamipretide) might help you

1. You are reading about PPIs (omeprazole, etc.) — what breaks down matters before any compound name.
2. Therefore for you: If mitochondrial function is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

SS-31 concentrates in the inner mitochondrial membrane and binds cardiolipin. This stabilizes the membrane, limits electron leak, and lowers reactive oxygen species output. If PPI-related nutrient gaps or other stressors have added oxidative burden to your mitochondria, this binding step could support cleaner energy production. The logic chain runs: better cardiolipin interaction → improved electron transport chain efficiency → potentially more ATP available for cellular repair tasks that acid suppression alone does not address.

## Why PPIs (omeprazole, etc.) matters for you

Drug: PPIs (omeprazole, etc.).
What it does: Acid suppression; long-term mucosal and nutrient consequences.
Therefore for you: This drug suppresses a signal (gastric acid) and reduces mechanical or symptomatic load on the esophagus and stomach. That suppression can trade off repair support by limiting nutrient uptake needed for mitochondrial and mucosal maintenance. The benefit is symptom control; the potential cost is slower resolution of underlying cellular strain if deficiencies accumulate.

## How these fit together

Single-compound focus. SS-31 targets the mitochondrial layer. PPIs handle acid-related load through suppression. The two address different points: one supports energy machinery inside cells, the other manages the primary driver of reflux. No direct synergy data exists; any overlap would depend on whether mitochondrial stress from nutrient shifts is active in a given person.

## What the evidence actually shows

Human data on SS-31 come from trials in primary mitochondrial myopathy and heart failure. One phase 1/2 dose-escalation study in adults with primary mitochondrial myopathy reported safety and some functional signals. A phase 3 trial (MMPOWER-3) followed. Results were mixed across programs; primary endpoints were not always met. Recent accelerated approval occurred for Barth syndrome based on muscle strength data from the TAZPOWER trial. No human trials examine SS-31 in people taking PPIs.

Preclinical work shows SS-31 improves mitochondrial respiration and reduces oxidative damage in aged or stressed rodent models, including kidney and cardiac tissue. These are animal findings and do not prove effects in PPI users.

For PPIs, large observational cohorts associate long-term use with nutrient deficiencies and renal risks. No randomized data prove causation for mitochondrial outcomes.

## What scientists say

Researchers describe SS-31 as a cardiolipin stabilizer that concentrates in mitochondria regardless of disease state. Reviews note consistent preclinical benefits on ROS and ATP but emphasize that clinical translation has been narrower than hoped. On PPIs, gastroenterology literature stresses short-term safety while flagging monitoring needs for deficiencies with prolonged use.

## What people say on Reddit

Anecdotal reports on SS-31 appear in communities focused on chronic fatigue or mitochondrial topics. One user described starting at low doses and noting initial fatigue and GI shifts that later eased with dose adjustment; another reported increased energy. These are individual experiences, not controlled observations, and no posts directly reference concurrent PPI use.

## What people say on X

Public posts discussing SS-31 and PPIs together are not prominent in available searches. Limited mentions of either compound appear separately, with no clear crossover anecdotes surfacing.

## What we do not know

No studies test whether SS-31 alters outcomes in PPI users. The mitochondrial-proton pump connection suggested in some commentary lacks direct measurement. Long-term nutrient effects of PPIs on mitochondrial markers remain unquantified in interventional designs.

## Safety and limits

SS-31 has shown an acceptable profile in completed human trials, with mild injection-site reactions noted most often. PPIs carry well-documented risks with extended use, primarily around absorption and infection susceptibility. Any combination remains unstudied. Evidence tiers here stay mechanistic or preclinical for the cross; human data are absent for the specific pairing.

## Claims (4)

- **c1** [human w=0.8] Long-term PPI use is associated with vitamin B12, magnesium, and calcium deficiencies in observational data.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [preclinical w=0.5] SS-31 binds cardiolipin in the inner mitochondrial membrane and reduces ROS in preclinical models.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c4** [mechanistic w=0.3] No human trials examine SS-31 in PPI users.
  - who_claims: grok/grok-4.3
- **c3** [human w=0.8] Human trials of SS-31 exist for primary mitochondrial myopathy and heart failure with mixed primary endpoint results; recent approval for Barth syndrome.
  - who_claims: grok/grok-4.3
  - sources: s3

## Voxel graph (4 atoms · 7 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-ppis/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (3)
- chain valid: yes · head: `a6893a6ccdaf56d5`

### s1 · review · ok
- title: Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC10248387/
- summary: Review summarizing observational links between PPIs and deficiencies.
- quote: The long-term use of PPIs has been linked to micronutrient deficiencies like hypomagnesemia, anemia, vitamin B12 deficiency, and hypocalcemia
- claim_ids: c1
- hash: `949ed679ed80807c`

### s2 · pubmed · ok
- title: The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria
- url: https://pubmed.ncbi.nlm.nih.gov/37462785/
- summary: Preclinical study on SS-31 mechanism.
- quote: Elamipretide (ELAM) rapidly improves physiological and mitochondrial function in aging and binds directly to the mitochondrial ADP transporter ANT.
- claim_ids: c2
- hash: `ffce76c66f07d427`

### s3 · clinical_trial · ok
- title: A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy
- url: https://clinicaltrials.gov/study/NCT03323749
- summary: Trial details confirming human study existence.
- quote: Phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety and efficacy of daily subcutaneous injections of elamipretide
- claim_ids: c3
- hash: `a6893a6ccdaf56d5`

## Provenance (2 model passes)
- chain valid: yes · head: `0275d2aef89b41a0`

- write · grok/grok-4.3 · 2026-06-29T23:48 · hash `7b274414ae88`
- voxel_divide · owner · 2026-07-17T02:42 · hash `0275d2aef89b`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-ppis/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-ppis/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-ppis","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-ppis|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-ppis|tier|assertion`
- **iMessage ask:** `ss-31-ppis|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-ppis`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-ppis/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-ppis/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*